Status:
COMPLETED
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
Lead Sponsor:
Vistakon Pharmaceuticals
Conditions:
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Eligibility:
All Genders
3+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
Eligibility Criteria
Inclusion
- healthy normal volunteers age \>=3 years with normal ocular health and a best-corrected logMAR score of 0.3 or better
- \-
Exclusion
- intraocular surgery and/or ocular surgical intervention within last 3 months, refractive surgery within last 6 months, active ocular disorder other than refractive disorders, breastfeeding women, pregnant female \< 18 years of age -
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT00223951
Start Date
September 1 2005
Last Update
February 20 2015
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85032
2
Bel Air, Maryland, United States, 21014
3
North Andover, Massachusetts, United States, 01845
4
Las Vegas, Nevada, United States, 89102